The Hyderabad-based pharmaceutical company Dr Reddy’s Laboratories Ltd has isolated all its data centre services across the world as a ‘preventive action’ after it detected a cyber attack on Thursday.
The data centre services are anticipated to be up within 24 hours and no major impact on operations are expected, said Mukesh Rathi, Dr Reddy’s chief information officer. The company official did not mention the source of attack on its IT infrastructure.
The company’s data breach holds significance as the drug maker is working on a Covid-19 vaccine. Last week, Dr Reddy’s had told Bombay Stock Exchange(BSE) that it has received approval from Drug Control General Of India(DGCI) to conduct mid-to-late-stage clinical trials of Russian Covid-19 vaccine candidate, Sputnik V, in India.
The company’s plants in India, Brazil, Russia, the UK and the US are reported to be impacted by the data breach. The attack has reportedly forced the firm to temporarily shut down the operations at its major manufacturing facilities.
According to the government official, the drug maker has stated that in phase 2 clinical trial, it would take 100 subjects and for phase 3 clinical trial, 1400 subjects would be taken. After the submission of safety and immunogenicity data of phase 2 trial, and analysis by the expert panel, the company will proceed to the phase 3 trial, the official said as reported by news agency ANI.
Apart from the Sputnik-V vaccine, the pharmaceutical company has tie-ups with global enterprises to sell coronavirus treatments favipiravir and remdesivir in India. The company is India’s second most valuable pharmaceuticals firm after Sun Pharma.It has 29 global offices in various continents.